Ginseng Power 5000 Capsules Recalled for Undeclared Prescription Drug Ingredients
NSNY Distributor Inc is recalling Ginseng Power 5000 capsules nationwide because they contain undeclared sildenafil and/or tadalafil, prescription medications not listed on the label or approved for sale in this product.
What this means for you
Highest-severity recall. Risk of serious injury or death is documented or strongly suspected. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The FDA classified this recall as Class I, which per the severity rubric automatically results in a Critical (5) rating. Class I recalls involve products marketed without approved applications that contain undeclared prescription drug ingredients—a serious safety violation.
Plain-English summary
NSNY Distributor Inc is recalling all lots of Ginseng Power 5000 capsules (1-count per blister card, UPC 0 40232 18144 3, manufactured by GS Natural Co, Los Angeles, CA 90010) distributed nationwide in the United States.
The product was marketed and sold without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) from the FDA. Testing found that the capsules contain undeclared sildenafil and/or tadalafil—prescription medications used to treat erectile dysfunction and pulmonary hypertension. These ingredients were not listed on the product label and were not approved for inclusion in this supplement.
Consumers who have purchased this product should not use it and should consult their healthcare provider if they have already taken it, particularly if they are taking other medications or have underlying health conditions that could interact with these undeclared prescription drugs. The product should be discarded or returned to the place of purchase.
The recalled product
- Product
- Ginseng Power 5000 capsule, 1- count per blister card, GS Natural Co, Los Angeles, CA 90010, UPC 0 40232 18144 3
- Manufacturer
- NSNY Distributor Inc
- Hazard
- undeclared-prescription-drug
- sildenafil
- tadalafil
- unapproved-drug
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- all lots
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27